vs
Axogen, Inc.（AXGN）与FONAR CORP（FONR）财务数据对比。点击上方公司名可切换其他公司
Axogen, Inc.的季度营收约是FONAR CORP的2.3倍（$59.9M vs $25.5M）。FONAR CORP净利率更高（8.0% vs -22.0%，领先30.0%）。Axogen, Inc.同比增速更快（21.3% vs 2.4%）。Axogen, Inc.自由现金流更多（$1.8M vs $-227.0K）。过去两年Axogen, Inc.的营收复合增速更高（20.3% vs -0.3%）
Axogen总部位于美国佛罗里达州阿拉楚阿，是外科解决方案提供商，专注开发周围神经损伤修复相关产品，涵盖人体组织移植物、神经连接器、软组织膜等，旗下AVANCE细胞移植技术可模拟人体神经结构，临床数据显示其产品帮助87%的周围神经损伤患者实现感觉与运动功能恢复，2013年完成1800万美元首次公开募股。
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
AXGN vs FONR — 直观对比
营收规模更大
AXGN
是对方的2.3倍
$25.5M
营收增速更快
AXGN
高出18.9%
2.4%
净利率更高
FONR
高出30.0%
-22.0%
自由现金流更多
AXGN
多$2.0M
$-227.0K
两年增速更快
AXGN
近两年复合增速
-0.3%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $59.9M | $25.5M |
| 净利润 | $-13.2M | $2.1M |
| 毛利率 | 74.1% | — |
| 营业利润率 | -16.3% | 13.5% |
| 净利率 | -22.0% | 8.0% |
| 营收同比 | 21.3% | 2.4% |
| 净利润同比 | -3023.6% | 4.7% |
| 每股收益（稀释后） | $-0.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXGNFONR
| Q4 25 | $59.9M | $25.5M | ||
| Q3 25 | $60.1M | $26.0M | ||
| Q2 25 | $56.7M | $27.3M | ||
| Q1 25 | $48.6M | $27.2M | ||
| Q4 24 | $49.4M | $24.9M | ||
| Q3 24 | $48.6M | $25.0M | ||
| Q2 24 | $47.9M | $25.9M | ||
| Q1 24 | $41.4M | $25.7M |
净利润AXGNFONR
| Q4 25 | $-13.2M | $2.1M | ||
| Q3 25 | $708.0K | $2.3M | ||
| Q2 25 | $579.0K | $729.3K | ||
| Q1 25 | $-3.8M | $2.5M | ||
| Q4 24 | $450.0K | $2.0M | ||
| Q3 24 | $-1.9M | $3.1M | ||
| Q2 24 | $-1.9M | $830.4K | ||
| Q1 24 | $-6.6M | $1.9M |
毛利率AXGNFONR
| Q4 25 | 74.1% | — | ||
| Q3 25 | 76.6% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 76.1% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 73.8% | — | ||
| Q1 24 | 78.8% | — |
营业利润率AXGNFONR
| Q4 25 | -16.3% | 13.5% | ||
| Q3 25 | 3.2% | 14.1% | ||
| Q2 25 | 3.0% | 5.3% | ||
| Q1 25 | -3.4% | 15.2% | ||
| Q4 24 | 4.1% | 11.9% | ||
| Q3 24 | -0.6% | 21.0% | ||
| Q2 24 | -0.9% | 7.4% | ||
| Q1 24 | -11.0% | 16.8% |
净利率AXGNFONR
| Q4 25 | -22.0% | 8.0% | ||
| Q3 25 | 1.2% | 8.7% | ||
| Q2 25 | 1.0% | 2.7% | ||
| Q1 25 | -7.9% | 9.2% | ||
| Q4 24 | 0.9% | 7.9% | ||
| Q3 24 | -3.8% | 12.6% | ||
| Q2 24 | -4.0% | 3.2% | ||
| Q1 24 | -16.0% | 7.3% |
每股收益（稀释后）AXGNFONR
| Q4 25 | $-0.28 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-0.00 | — | ||
| Q3 24 | $-0.04 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.15 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.5M | $121.0K |
| 总债务越低越好 | $48.4M | — |
| 股东权益账面价值 | $128.8M | $176.9M |
| 总资产 | $221.7M | $217.2M |
| 负债/权益比越低杠杆越低 | 0.38× | — |
8季度趋势，按日历期对齐
现金及短期投资AXGNFONR
| Q4 25 | $41.5M | $121.0K | ||
| Q3 25 | $35.8M | $122.0K | ||
| Q2 25 | $29.9M | $56.5M | ||
| Q1 25 | $22.1M | $123.0K | ||
| Q4 24 | $33.5M | $121.0K | ||
| Q3 24 | $24.5M | $136.0K | ||
| Q2 24 | $21.1M | $56.5M | ||
| Q1 24 | $17.6M | $134.0K |
总债务AXGNFONR
| Q4 25 | $48.4M | — | ||
| Q3 25 | $48.2M | — | ||
| Q2 25 | $47.9M | — | ||
| Q1 25 | $47.7M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $47.3M | — | ||
| Q2 24 | $47.0M | $66.9K | ||
| Q1 24 | $46.8M | — |
股东权益AXGNFONR
| Q4 25 | $128.8M | $176.9M | ||
| Q3 25 | $120.8M | $174.9M | ||
| Q2 25 | $112.3M | $172.6M | ||
| Q1 25 | $105.4M | $171.9M | ||
| Q4 24 | $103.9M | $169.8M | ||
| Q3 24 | $99.4M | $168.7M | ||
| Q2 24 | $95.7M | $166.0M | ||
| Q1 24 | $93.2M | $165.8M |
总资产AXGNFONR
| Q4 25 | $221.7M | $217.2M | ||
| Q3 25 | $216.4M | $218.4M | ||
| Q2 25 | $205.5M | $216.9M | ||
| Q1 25 | $196.2M | $214.9M | ||
| Q4 24 | $203.7M | $208.0M | ||
| Q3 24 | $192.0M | $212.3M | ||
| Q2 24 | $188.9M | $214.2M | ||
| Q1 24 | $186.5M | $209.6M |
负债/权益比AXGNFONR
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.49× | 0.00× | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $171.0K |
| 自由现金流经营现金流 - 资本支出 | $1.8M | $-227.0K |
| 自由现金流率自由现金流/营收 | 3.0% | -0.9% |
| 资本支出强度资本支出/营收 | 2.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $5.7M |
8季度趋势，按日历期对齐
经营现金流AXGNFONR
| Q4 25 | $3.0M | $171.0K | ||
| Q3 25 | $3.2M | $1.7M | ||
| Q2 25 | $7.7M | $4.2M | ||
| Q1 25 | $-13.2M | $3.1M | ||
| Q4 24 | $8.7M | $2.2M | ||
| Q3 24 | $3.9M | $1.7M | ||
| Q2 24 | $4.2M | $4.6M | ||
| Q1 24 | $-12.3M | $2.8M |
自由现金流AXGNFONR
| Q4 25 | $1.8M | $-227.0K | ||
| Q3 25 | $1.7M | $-177.0K | ||
| Q2 25 | $7.0M | $3.6M | ||
| Q1 25 | $-13.4M | $2.6M | ||
| Q4 24 | $8.1M | $1.5M | ||
| Q3 24 | $3.3M | $-148.0K | ||
| Q2 24 | $3.3M | $4.2M | ||
| Q1 24 | $-13.2M | $2.6M |
自由现金流率AXGNFONR
| Q4 25 | 3.0% | -0.9% | ||
| Q3 25 | 2.8% | -0.7% | ||
| Q2 25 | 12.4% | 13.1% | ||
| Q1 25 | -27.7% | 9.4% | ||
| Q4 24 | 16.3% | 6.0% | ||
| Q3 24 | 6.8% | -0.6% | ||
| Q2 24 | 6.8% | 16.1% | ||
| Q1 24 | -31.9% | 10.2% |
资本支出强度AXGNFONR
| Q4 25 | 2.1% | 1.6% | ||
| Q3 25 | 2.5% | 7.2% | ||
| Q2 25 | 1.3% | 2.4% | ||
| Q1 25 | 0.5% | 2.2% | ||
| Q4 24 | 1.4% | 3.0% | ||
| Q3 24 | 1.2% | 7.2% | ||
| Q2 24 | 1.9% | 1.6% | ||
| Q1 24 | 2.2% | 0.7% |
现金转化率AXGNFONR
| Q4 25 | — | 0.08× | ||
| Q3 25 | 4.55× | 0.75× | ||
| Q2 25 | 13.35× | 5.79× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | 19.41× | 1.14× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXGN
暂无分部数据
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
